Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioma 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Medulloblastoma 7Lung Neoplasms 7Wilms Tumor 6Sarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Neoplasm Metastasis 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Central Nervous System Neoplasms 6Rhabdomyosarcoma 5Lymphoma 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Multiple Myeloma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma, Ewing 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Leukemia, Myeloid, Acute 3Stomach Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Granulosa cell tumor of the ovary × X-Rays × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡